CU24301B1 - Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) - Google Patents

Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3)

Info

Publication number
CU24301B1
CU24301B1 CUP2015000097A CU20150097A CU24301B1 CU 24301 B1 CU24301 B1 CU 24301B1 CU P2015000097 A CUP2015000097 A CU P2015000097A CU 20150097 A CU20150097 A CU 20150097A CU 24301 B1 CU24301 B1 CU 24301B1
Authority
CU
Cuba
Prior art keywords
type
angptl3
angiopoyetina
polypeptide
joint
Prior art date
Application number
CUP2015000097A
Other languages
English (en)
Spanish (es)
Other versions
CU20150097A7 (es
Inventor
Kristen Johnson
Jian Shi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20150097A7 publication Critical patent/CU20150097A7/es
Publication of CU24301B1 publication Critical patent/CU24301B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
CUP2015000097A 2013-03-08 2014-03-07 Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3) CU24301B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201461938123P 2014-02-10 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (2)

Publication Number Publication Date
CU20150097A7 CU20150097A7 (es) 2016-05-30
CU24301B1 true CU24301B1 (es) 2017-12-08

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000097A CU24301B1 (es) 2013-03-08 2014-03-07 Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3)

Country Status (38)

Country Link
US (4) US9649359B2 (ar)
EP (2) EP3391900B1 (ar)
JP (3) JP6567429B2 (ar)
KR (1) KR102267341B1 (ar)
CN (2) CN111808182A (ar)
AP (1) AP2015008675A0 (ar)
AU (3) AU2014225348B2 (ar)
BR (2) BR122016021558B1 (ar)
CA (1) CA2903448C (ar)
CL (1) CL2015002443A1 (ar)
CO (1) CO7461145A2 (ar)
CR (2) CR20200290A (ar)
CU (1) CU24301B1 (ar)
CY (1) CY1120729T1 (ar)
DK (1) DK2964250T3 (ar)
EA (1) EA035158B1 (ar)
EC (1) ECSP15042898A (ar)
ES (1) ES2684349T3 (ar)
HR (1) HRP20181269T1 (ar)
HU (1) HUE038499T2 (ar)
IL (1) IL240727B (ar)
JO (1) JO3564B1 (ar)
LT (1) LT2964250T (ar)
MX (1) MX365157B (ar)
MY (1) MY173172A (ar)
NZ (1) NZ711037A (ar)
PE (1) PE20151528A1 (ar)
PH (1) PH12015501983B1 (ar)
PL (1) PL2964250T3 (ar)
PT (1) PT2964250T (ar)
RS (1) RS57446B1 (ar)
SG (1) SG11201506490TA (ar)
SI (1) SI2964250T1 (ar)
TN (1) TN2015000385A1 (ar)
TW (1) TWI634124B (ar)
UY (1) UY35368A (ar)
WO (1) WO2014138687A1 (ar)
ZA (1) ZA201505966B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
CN109891632A (zh) 2016-10-24 2019-06-14 住友化学株式会社 间隔件、和包含间隔件的二次电池
AU2017358282C1 (en) * 2016-11-09 2020-11-26 Icm Co., Ltd. Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
TW202027794A (zh) * 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
KR102577697B1 (ko) * 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN117355323A (zh) 2021-05-24 2024-01-05 诺华股份有限公司 用于治疗骨关节炎的方法
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
WO2023084388A1 (en) 2021-11-10 2023-05-19 Novartis Ag Methods for determining the biological activity of angptl polypeptides
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR102971681B1 (ko) * 2022-12-09 2026-06-02 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
AU2025220507A1 (en) 2024-02-05 2026-07-23 Novartis Ag Improved production of angptl3 mimetics
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
JP2003531811A (ja) 1999-03-08 2003-10-28 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ATE368110T1 (de) 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
AU2437702A (en) 2000-10-16 2002-04-29 Genentech Inc Methods of treatment using wisp polypeptides
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
KR20100029861A (ko) * 2001-11-16 2010-03-17 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
JP4764630B2 (ja) 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
EP1558747B1 (en) 2002-10-16 2009-10-14 The Scripps Research Institute Glycoprotein synthesis
MXPA05003983A (es) 2002-10-16 2005-06-22 Scripps Research Inst Incorporacion en sitio especifico de cetoaminoacidos en proteinas.
JP5642916B2 (ja) 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
EP1704242A4 (en) 2003-07-07 2008-06-18 Scripps Research Inst COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
MX2007003142A (es) 2004-09-21 2007-07-04 Scripps Research Inst Incorporacion in vivo de alquinil aminoacidos a proteinas en eubacterias.
MX2007004892A (es) 2004-10-27 2007-08-16 Scripps Research Inst Componentes de traduccion ortogonales para la incorporacion in vivo de aminoacidos no naturales.
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2006127809A2 (en) 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
MX2008011470A (es) 2006-03-09 2008-09-24 Scripps Research Inst Sistemas para la expresion de componentes de traduccion ortogonales en celulas huesped eubacterianas.
KR101460815B1 (ko) 2006-12-06 2014-11-12 세이가가쿠 고교 가부시키가이샤 관절염 질환 치료의 지속성 효과를 갖는 제약 제제
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
EP2155862A2 (en) 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
PE20160507A1 (es) * 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage

Also Published As

Publication number Publication date
US9649359B2 (en) 2017-05-16
CR20150466A (es) 2015-10-27
US20220184182A1 (en) 2022-06-16
NZ711037A (en) 2018-07-27
ZA201505966B (en) 2017-03-29
AP2015008675A0 (en) 2015-08-31
BR122016021558A2 (pt) 2019-07-30
UY35368A (es) 2014-10-31
CR20200290A (es) 2020-08-27
PH12015501983A1 (en) 2016-01-11
ES2684349T3 (es) 2018-10-02
ECSP15042898A (es) 2019-03-29
AU2016203028A1 (en) 2016-05-26
IL240727A0 (en) 2015-10-29
BR122016021558B1 (pt) 2023-03-28
JP6918871B2 (ja) 2021-08-11
AU2016203028C1 (en) 2017-06-01
BR112015021269A2 (pt) 2017-10-10
WO2014138687A1 (en) 2014-09-12
US20170252407A1 (en) 2017-09-07
CN105025917B (zh) 2020-08-18
EA201591661A1 (ru) 2015-12-30
HRP20181269T1 (hr) 2018-10-19
MX2015011963A (es) 2015-12-09
CN105025917A (zh) 2015-11-04
AU2016277608B2 (en) 2018-04-05
EP3391900A1 (en) 2018-10-24
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
MX365157B (es) 2019-05-24
IL240727B (en) 2019-12-31
TN2015000385A1 (en) 2017-01-03
JP6567429B2 (ja) 2019-08-28
JP2020015725A (ja) 2020-01-30
US10328126B2 (en) 2019-06-25
EA035158B1 (ru) 2020-05-06
PH12015501983B1 (en) 2020-09-25
EP3391900B1 (en) 2026-07-01
JP2016510763A (ja) 2016-04-11
HUE038499T2 (hu) 2018-10-29
SG11201506490TA (en) 2015-09-29
EP2964250B1 (en) 2018-05-16
CY1120729T1 (el) 2019-12-11
BR112015021269B1 (pt) 2023-04-11
LT2964250T (lt) 2018-07-25
TWI634124B (zh) 2018-09-01
RS57446B1 (sr) 2018-09-28
JP2021178841A (ja) 2021-11-18
KR20150125712A (ko) 2015-11-09
AU2016277608A1 (en) 2017-01-12
JO3564B1 (ar) 2020-07-05
CA2903448C (en) 2021-03-23
US11179442B2 (en) 2021-11-23
TW201444865A (zh) 2014-12-01
AU2014225348A1 (en) 2015-09-10
US20160008433A1 (en) 2016-01-14
CA2903448A1 (en) 2014-09-12
CN111808182A (zh) 2020-10-23
PL2964250T3 (pl) 2018-10-31
AU2016203028B2 (en) 2017-02-02
US20200268849A1 (en) 2020-08-27
AU2014225348B2 (en) 2016-03-31
PT2964250T (pt) 2018-10-19
DK2964250T3 (da) 2018-08-06
EP2964250A1 (en) 2016-01-13
KR102267341B1 (ko) 2021-06-21
HK1214754A1 (en) 2016-08-05
CU20150097A7 (es) 2016-05-30
MY173172A (en) 2020-01-02
CL2015002443A1 (es) 2016-05-20
CO7461145A2 (es) 2015-11-30

Similar Documents

Publication Publication Date Title
CU20150097A7 (es) Variantes de polipéptidos y proteínas de angiopoyetina-tipo 3 (angptl3)
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
EA201792245A1 (ru) Биоконъюгаты и их применения
CO7151525A2 (es) Proteínas del factor 21 de crecimiento del fibroblasto
UY33739A (es) Metodos de tratamiento de trastornos asociados con el fgf21
GB202006164D0 (en) Recombinant collagen and eslastin molecules and uses thereof
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
CR20160049A (es) Bioconjugados de polipéptidos de apelina sintética
DK3538559T3 (da) Rekombinante pmhc klasse ii-molekyler
BR112018007453A2 (pt) genes modificados de ataxia de friedreich e vetores para a terapia gênica
MX376324B (es) Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
PL3744731T3 (pl) Białka fuzyjne FGF21 o przedłużonym działaniu i kompozycja farmaceutyczna je zawierająca
MX384628B (es) Polipéptidos que tienen actividad de transgalactosilación.
EA201591839A1 (ru) Терапевтические пептиды
CR20180292A (es) Productos de contrucción que comprenden grafeno u óxido de grafeno en el material granel y procedimiento para la producción de tales productos de construcción
DK3619324T3 (da) Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf
CL2020000733A1 (es) Proteína de fusión que comprende una porción de fgf-18.
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
IL262356A (en) Polyethylene glycol-converted bioactive peptides and their uses
DK3630793T3 (da) Rekombinant protein
BR112019005959A2 (pt) gene dgkk recombinante para terapia genética da síndrome do x frágil
EP3556370A4 (en) OPHTHALMIC COMPOSITION CONTAINING SULFASALAZINE AND HYALURONIC ACID
DK3532111T3 (da) Bioaktiv knoglesammensætning og anvendelser deraf